High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
An article from
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
Published May 22, 2026
Biogen and Denali Therapeutics have been working on a Parkinson's disease drug under an alliance formed in 2020.
Getty Images
Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Pharmalittle: We're reading about a Parkinson's drug setback, a Merck lung cancer therapy, and more
EU and US advisers split over AstraZeneca breast cancer drug
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
Rethinking Clinical Trials with Faster AI-Driven Decision Making
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Parabilis reveals IPO plans the day after Regeneron deal as listings heat up
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the…
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies…
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
